Selecting Hypoxic Tumours for Treatment Modification

Launched by UNIVERSITY OF MANCHESTER · Jan 15, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating a new way to improve treatment for patients with bladder and prostate cancer who have what are called "hypoxic tumours." These tumours do not get enough oxygen, making them harder to treat with standard radiotherapy. The researchers have developed a special test that looks at gene activity in tumours to identify which patients have hypoxic tumours. By identifying these patients, doctors can provide more effective treatments, potentially improving outcomes. The goal of the study is to show that this gene test can help predict which patients will benefit from specific treatments designed to enhance the effects of radiotherapy.

To participate in this trial, patients must be at least 18 years old and receiving radiotherapy at the Christie NHS Foundation Trust. They also need to be able to undergo MRI scans and give informed consent to join the study. If eligible, participants can expect to undergo additional imaging and receive tailored treatment based on the results of the gene test. It’s important to note that the trial is currently recruiting participants, and all involved will be closely monitored throughout the process to ensure their safety and the effectiveness of the treatment modifications.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • This will be tumour site dependent.
• Bladder:
• • Older than age 18 years.
• • Patients having radiotherapy at the Christie NHS Foundation Trust suitable for imaging on an MRI scanner.
• • Able to give informed consent.
• Cervix:
• • Older than age 18 years.
• • Patients having radiotherapy at the Christie NHS Foundation Trust suitable for imaging on an MRI scanner.
• • Able to give informed consent.
• Prostate:
• • Older than age 18 years.
• • Patients having radiotherapy at the Christie NHS Foundation Trust suitable for imaging on an MRI scanner.
• • Able to give informed consent.
• Exclusion Criteria:
• • This will be tumour site dependent
• Bladder:
• • Any contraindications to MRI identified after MRI safety screening including completion of an MRI Safety Screening Form.
• • Unable to tolerate MRI scans.
• • Pregnancy.
• Cervix:
• • Any contraindications to MRI identified after MRI safety screening including completion of an MRI Safety Screening Form.
• • Unable to tolerate MRI scans.
• • Pregnancy.
• Prostate:
• • Any contraindications to MRI identified after MRI safety screening including completion of an MRI Safety Screening Form.
• • Unable to tolerate MRI scans